AllianceBernstein
CTXR icon

AllianceBernstein’s Citius Pharmaceuticals CTXR Stock Holding History

AllianceBernstein’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-450
Closed -$10.1K – 3250
2024
Q1 		$10.1K Hold
450
– – ﹤0.01% 3133
2023
Q4 		$8.51K Hold
450
– – ﹤0.01% 3176
2023
Q3 		$7.7K Sell
450
-450
-50% -$10.7K ﹤0.01% 3179
2023
Q2 		$27K Buy
+900
New +$29.6K ﹤0.01% 3150
2022
Q2 		– Sell
-8,372
Closed -$375K – 3288
2022
Q1 		$375K Buy
8,372
+28
+0.3% +$1.11K ﹤0.01% 2792
2021
Q4 		$321K Hold
8,344
– – ﹤0.01% 2924
2021
Q3 		$423K Hold
8,344
– – ﹤0.01% 2820
2021
Q2 		$726K Buy
+8,344
New +$501K ﹤0.01% 2659

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's CTXR Position: Q2 2024 in Review

AllianceBernstein sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 450 shares — an estimated $10.1K sold.

AllianceBernstein first reported a position in CTXR in Q2 2021 and held it in 8 quarters. The position peaked at $726K in Q2 2021. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • AllianceBernstein reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • AllianceBernstein sold 450 Citius Pharmaceuticals shares in Q2 2024, an estimated $10.1K.
  • AllianceBernstein first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • AllianceBernstein's Citius Pharmaceuticals position peaked at $726K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.